<DOC>
	<DOCNO>NCT02065440</DOCNO>
	<brief_summary>To determine whether ebastine/pseudoephedrine effective subacute cough .</brief_summary>
	<brief_title>The Effect Ebastine/Pseudoephedrine Subacute Cough</brief_title>
	<detailed_description>1 . Visit 0 week - Patients subacute cough , area randomize either ebastine/pseudoephedrine placebo 1 week . - The cough severity quality life measure VAS score cough-specific quality-of-life questionnaire ( CQLQ ) 2 . Visit 1 week check VAS score CQLQ 3 . Visit 4 week check VAS score CQLQ</detailed_description>
	<mesh_term>Cough</mesh_term>
	<mesh_term>Pseudoephedrine</mesh_term>
	<mesh_term>Ephedrine</mesh_term>
	<mesh_term>Ebastine</mesh_term>
	<criteria>patient subacute cough ( 38 week ) age : 2070 year Chest Xray abnormality ( + ) probable cause cough explainable confirm diagnosis ( + ) acute infectious disease Severe cough cough complication need antitussive agent . ACEI three hypertensive agent change hypertension medication 3 month ago immunocompromized host relative absolute contraindication ebastine/pseudoephedrine 1. hypersensitivity ebastine/pseudoephedrine 2. glaucoma 3. moderate severe hypertensive disease 4. coronary heart disease 5. hyperthyroidism 6. moderate severe liver disease 7. benign prostate hyperplasia 8. psychological problem 9 . Parkinson 's disease 10. linezolid suppose use .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Ebastine/Pseudoephedrine</keyword>
	<keyword>subacute cough</keyword>
	<keyword>upper airway cough syndrome</keyword>
</DOC>